Galvokimig

BIOLOGICAL4 trials

Sponsors

UCB Biopharma, UCB Biopharma SRL

Conditions

Atopic DermatitisChronic Obstructive Pulmonary Disease With Chronic BronchitisNon-cystic Fibrosis Bronchiectasis

Phase 2

A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis

RecruitingNCT07277660

UCB Biopharma SRLAtopic Dermatitis

Start: 2025-12-29End: 2028-03-06Target: 160Updated: 2026-09-11

A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF GALVOKIMIG IN ADULT STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS

Not yet recruitingCTIS2025-522578-35-00

UCB BiopharmaAtopic Dermatitis

Target: 22Updated: 2026-03-10

A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Adult Study Participants With Non-Cystic Fibrosis Bronchiectasis

RecruitingNCT07720375

UCB Biopharma SRLNon-cystic Fibrosis Bronchiectasis

Start: 2026-08-05End: 2029-04-26Target: 300Updated: 2026-09-11

A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis

RecruitingNCT07725939

UCB Biopharma SRLChronic Obstructive Pulmonary Disease With Chronic Bronchitis

Start: 2026-07-27End: 2029-06-29Target: 402Updated: 2026-09-15